HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 6 (June)

1. Solution structure and thermodynamic investigation of the HIV-1 frameshift inducing element.
   J Mol Biol, 349(5): 1011-23. [Abstract] [Full-text]
2. Structure of the RNA signal essential for translational frameshifting in HIV-1.
   J Mol Biol, 349(5): 1024-35. [Abstract] [Full-text]
3. Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazoles as novel Capravirine analogues.
   Bioorg Med Chem, 13(13): 4209-20. [Abstract] [Full-text]
4. Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons.
   Genes Immun, 6(4): 371-4. [Abstract] [Full-text]
5. Sesquiterpenes and butenolides, natural anti-HIV constituents from Litsea verticillata.
   Planta Med, 71(5): 452-7. [Abstract] [Full-text]
6. Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa.
   AIDS Res Hum Retroviruses, 21(5): 430-3. [Abstract] [Full-text]
7. Characterization of complete HIV type 1 genomes from non-B subtype infections in U.S. military personnel.
   AIDS Res Hum Retroviruses, 21(5): 424-9. [Abstract] [Full-text]
8. Detection of a new 3-base pair insertion mutation in the protease gene of human immunodeficiency virus type 1 during highly active antiretroviral therapy (HAART).
   AIDS Res Hum Retroviruses, 21(5): 420-3. [Abstract] [Full-text]
9. Sequence analysis of near full-length HIV type 1 subtype D primary strains isolated in Cape Town, South Africa, from 1984 to 1986.
   AIDS Res Hum Retroviruses, 21(5): 410-3. [Abstract] [Full-text]
10. A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1.
    AIDS Res Hum Retroviruses, 21(5): 395-7. [Abstract] [Full-text]
11. Identification of a region within the cytoplasmic domain of the subtype B Vpu protein of human immunodeficiency virus type 1 (HIV-1) that is responsible for retention in the golgi complex and its absence in the Vpu protein from a subtype C HIV-1.
    AIDS Res Hum Retroviruses, 21(5): 379-94. [Abstract] [Full-text]
12. Lymphoid follicles are sites of heightened human immunodeficiency virus type 1 (HIV-1) replication and reduced antiretroviral effector mechanisms.
    AIDS Res Hum Retroviruses, 21(5): 363-70. [Abstract] [Full-text]
13. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance.
    AIDS Res Hum Retroviruses, 21(5): 343-57. [Abstract] [Full-text]
14. Thrombectomy in HIV related peripheral arterial thrombosis: a preliminary report.
    Eur J Vasc Endovasc Surg, 30(1): 102-6. [Abstract] [Full-text]
15. AIDS-related knowledge, attitudes and behavior among adolescents in Zambia.
    AIDS Behav, 9(2): 223-31. [Abstract] [Full-text]
16. Trends of HIV risk behaviors in a cohort of injecting drug users and their sex partners in Miami, Florida, 1988-1998.
    AIDS Behav, 9(2): 187-99. [Abstract] [Full-text]
17. Risk Perception and sexual risk behaviors among HIV-positive men on antiretroviral therapy.
    AIDS Behav, 9(2): 167-76. [Abstract] [Full-text]
18. Partner awareness of the serostatus of HIV-seropositive men who have sex with men: impact on unprotected sexual behavior.
    AIDS Behav, 9(2): 155-66. [Abstract] [Full-text]
19. Development of a brief scale to measure AIDS-related stigma in South Africa.
    AIDS Behav, 9(2): 135-43. [Abstract] [Full-text]
20. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75.
    Nat Struct Mol Biol, 12(6): 526-32. [Abstract] [Full-text]
21. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions.
    Dis Colon Rectum, 48(5): 1042-54. [Abstract] [Full-text]
22. HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation.
    Blood, 105(12): 4693-9. [Abstract] [Full-text]
23. Impaired base excision repair and accumulation of oxidative base lesions in CD4+ T cells of HIV-infected patients.
    Blood, 105(12): 4730-5. [Abstract] [Full-text]
24. The HIV coreceptor switch: a population dynamical perspective.
    Trends Microbiol, 13(6): 269-77. [Abstract] [Full-text]
25. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
    Trends Microbiol, 13(6): 243-6. [Abstract] [Full-text]
26. Specific inhibition of HIV-1 replication by short hairpin RNAs targeting human cyclin T1 without inducing apoptosis.
    FEBS Lett, 579(14): 3100-6. [Abstract] [Full-text]
27. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
    Nat Med, 11(6): 615-22. [Abstract] [Full-text]
28. Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.
    J Biol Chem, 280(23): 21987-96. [Abstract] [Full-text]
29. Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction.
    Exp Eye Res, 80(6): 787-94. [Abstract] [Full-text]
30. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
    J Gene Med, 7(6): 818-34. [Abstract] [Full-text]
31. Inhibition of HIV-1 replication in human lymphoid tissues ex vivo by measles virus.
    J Infect Dis, 192(1): 71-8. [Abstract] [Full-text]
32. Identification of attenuated variants of HIV-1 circulating recombinant form 01_AE that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences.
    J Infect Dis, 192(1): 56-61. [Abstract] [Full-text]
33. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts.
    J Infect Dis, 192(1): 46-55. [Abstract] [Full-text]
34. HIV-1 subtype diversity in Minnesota.
    J Infect Dis, 192(1): 37-45. [Abstract] [Full-text]
35. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
    J Infect Dis, 192(1): 30-6. [Abstract] [Full-text]
36. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
    J Infect Dis, 192(1): 24-9. [Abstract] [Full-text]
37. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
    J Infect Dis, 192(1): 16-23. [Abstract] [Full-text]
38. HIV dynamics with multiple infections of target cells.
    Proc Natl Acad Sci U S A, 102(23): 8198-203. [Abstract] [Full-text]
39. Is it possible to reduce AIDS deaths without reinforcing socioeconomic inequalities in health?
    Int J Epidemiol, 34(3): 586-92. [Abstract] [Full-text]
40. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival.
    Int J Epidemiol, 34(3): 577-84. [Abstract] [Full-text]
41. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    AIDS Res Hum Retroviruses, 21(4): 319-24. [Abstract] [Full-text]
42. Characterization of intersubtype recombinant HIV type 1 genomes using a nonradioactive heteroduplex tracking assay.
    AIDS Res Hum Retroviruses, 21(4): 314-8. [Abstract] [Full-text]
43. New two-amino acid insertion near codon 70 of the HIV type 1 protease gene.
    AIDS Res Hum Retroviruses, 21(4): 311-3. [Abstract] [Full-text]
44. High genetic diversity of human immunodeficiency virus type 1 in Angola.
    AIDS Res Hum Retroviruses, 21(4): 306-10. [Abstract] [Full-text]
45. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India.
    AIDS Res Hum Retroviruses, 21(4): 301-5. [Abstract] [Full-text]
46. Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa.
    AIDS Res Hum Retroviruses, 21(4): 285-91. [Abstract] [Full-text]
47. Seroprevalence and risk factors for human T cell lymphotropic virus type 1 and 2 infection in human immunodeficiency virus-infected patients attending AIDS referral center health units in Londrina and other communities in Paraná, Brazil.
    AIDS Res Hum Retroviruses, 21(4): 256-62. [Abstract] [Full-text]
48. Prevalence and molecular characterization of human T cell leukemia virus type 2 in a group of intravenous drug users coinfected with HIV type 1 in Portugal.
    AIDS Res Hum Retroviruses, 21(4): 249-55. [Abstract] [Full-text]
49. Multiple HIV-related aneurysms: open and endovascular treatment.
    J Endovasc Ther, 12(3): 405-10. [Abstract] [Full-text]
50. Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism.
    J Med Chem, 48(12): 3949-52. [Abstract] [Full-text]
51. Regional patterns of the temporal evolution of the AIDS epidemic in Brazil following the introduction of antiretroviral therapy.
    Braz J Infect Dis, 9(1): 9-19. [Abstract] [Full-text]
52. Discordant molecular characterization results in a Mycobacterium avium complex strain isolated from an AIDS patient.
    J Med Microbiol, 54: 681-3. [Abstract] [Full-text]
53. HIV/AIDS in women: an expanding epidemic.
    Science, 308(5728): 1582-3. [Abstract] [Full-text]
54. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
    J Antimicrob Chemother, 55(6): 872-8. [Abstract] [Full-text]
55. High correlation of human immunodeficiency virus type-1 viral load measured in dried-blood spot samples and in plasma under different storage conditions.
    Arch Med Res, 36(4): 382-6. [Abstract] [Full-text]
56. Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role?
    Ann Trop Med Parasitol, 99(4): 395-402. [Abstract] [Full-text]
57. Inflammatory pseudotumor of the testis: a novel presentation of acute retroviral syndrome.
    Int J Urol, 12(4): 424-6. [Abstract] [Full-text]
58. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome.
    Virology, 337(2): 384-98. [Abstract] [Full-text]
59. Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex.
    Virology, 337(2): 242-52. [Abstract] [Full-text]
60. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function.
    Virology, 337(2): 284-96. [Abstract] [Full-text]
61. Phenotypic and kinetic analysis of effective simian-human immunodeficiency virus-specific T cell responses in DNA--and fowlpox virus-vaccinated macaques.
    Virology, 337(2): 222-34. [Abstract] [Full-text]
62. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
    Antiviral Res, 67(1): 1-9. [Abstract] [Full-text]
63. Tilt angle of a trans-membrane helix is determined by hydrophobic mismatch.
    J Mol Biol, 350(2): 310-8. [Abstract] [Full-text]
64. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1.
    Gene, 353(1): 8-15. [Abstract] [Full-text]
65. Detection of human immunodeficiency virus type 1 Nef and CD4 physical interaction in living human cells by using bioluminescence resonance energy transfer.
    J Virol, 79(13): 8629-36. [Abstract] [Full-text]
66. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.
    J Virol, 79(13): 8454-69. [Abstract] [Full-text]
67. Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes.
    J Virol, 79(13): 8440-53. [Abstract] [Full-text]
68. Wild-type-like viral replication potential of human immunodeficiency virus type 1 envelope mutants lacking palmitoylation signals.
    J Virol, 79(13): 8374-87. [Abstract] [Full-text]
69. In-depth, longitudinal analysis of viral quasispecies from an individual triply infected with late-stage human immunodeficiency virus type 1, using a multiple PCR primer approach.
    J Virol, 79(13): 8249-61. [Abstract] [Full-text]
70. Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells.
    J Virol, 79(13): 8208-16. [Abstract] [Full-text]
71. Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection.
    J Virol, 79(13): 8171-81. [Abstract] [Full-text]
72. Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants.
    J Virol, 79(13): 8121-30. [Abstract] [Full-text]
73. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape.
    J Virol, 79(13): 7990-8003. [Abstract] [Full-text]
74. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells.
    J Virol, 79(13): 7959-66. [Abstract] [Full-text]
75. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting.
    J Clin Microbiol, 43(6): 2709-17. [Abstract] [Full-text]
76. HIV-1 interaction with human mannose receptor (hMR) induces production of matrix metalloproteinase 2 (MMP-2) through hMR-mediated intracellular signaling in astrocytes.
    Biochim Biophys Acta, 1741(1): 55-64. [Abstract] [Full-text]
77. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use.
    Addiction, 100(7): 990-1002. [Abstract] [Full-text]
78. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain.
    Addiction, 100(7): 981-9. [Abstract] [Full-text]
79. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors.
    Proc Natl Acad Sci U S A, 102(24): 8764-9. [Abstract] [Full-text]
80. Human immunodeficiency virus 1 (HIV-1) envelope-dependent cell-cell fusion modulation by HIV-positive sera is related to disease progression.
    J Gen Virol, 86: 1961-6. [Abstract] [Full-text]
81. Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.
    Clin Exp Immunol, 141(1): 72-80. [Abstract] [Full-text]
82. Lentivirus-mediated transduction of PKR into CD34(+) hematopoietic stem cells inhibits HIV-1 replication in differentiated T cell progeny.
    J Interferon Cytokine Res, 25(6): 345-60. [Abstract] [Full-text]
83. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection.
    J Infect Dis, 192(2): 303-10. [Abstract] [Full-text]
84. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.
    Clin Pharmacol Ther, 77(6): 515-28. [Abstract] [Full-text]
85. HIV-positive patients and the doctor-patient relationship: perspectives from the margins.
    Qual Health Res, 15(6): 791-806. [Abstract] [Full-text]
86. Developments in STD/HIV interactions: the intertwining epidemics of HIV and HSV-2.
    Infect Dis Clin North Am, 19(2): 415-25. [Abstract] [Full-text]
87. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells.
    J Exp Med, 201(12): 2023-33. [Abstract] [Full-text]
88. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease.
    J Exp Med, 201(12): 1999-2010. [Abstract] [Full-text]
89. Comparative evaluation of the VIDAS HIV DUO Ultra assay for combined detection of HIV-1 antigen and antibodies to HIV.
    J Virol Methods, 127(2): 165-7. [Abstract] [Full-text]
90. The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation.
    Biochemistry, 44(25): 9058-66. [Abstract] [Full-text]
91. Novel method of inactivation of human immunodeficiency virus type 1 by the freeze pressure generation method.
    Appl Microbiol Biotechnol, 67(6): 746-51. [Abstract] [Full-text]
92. Anti-HIV bioactive stilbene dimers of Caragana rosea.
    Planta Med, 71(6): 569-71. [Abstract] [Full-text]
93. Unprotected anal intercourse in HIV-positive and HIV-negative gay men: the relevance of sexual arousability, mood, sensation seeking, and erectile problems.
    Arch Sex Behav, 34(3): 299-305. [Abstract] [Full-text]
94. Complementary therapies for the treatment of HIV: in search of the evidence.
    Int J STD AIDS, 16(6): 395-403. [Abstract] [Full-text]
95. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1.
    Infect Immun, 73(7): 4155-60. [Abstract] [Full-text]
96. Causative agents of liver abscess in HIV-seropositive patients: a 10-year case series in Thai hospitalized patients.
    Trop Doct, 35(2): 115-7. [Abstract] [Full-text]
97. Identification of a major restriction in HIV-1 intersubtype recombination.
    Proc Natl Acad Sci U S A, 102(25): 9002-7. [Abstract] [Full-text]
98. The host environment drives HIV-1 fitness.
    Rev Med Virol, 15(4): 219-33. [Abstract] [Full-text]
99. Genotypic distribution of human herpesvirus-8 strains circulating in HIV-positive patients with and without Kaposi's sarcoma in Hungary.
    Arch Virol, 150(7): 1315-26. [Abstract] [Full-text]
100. Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
     J Med Chem, 48(13): 4378-88. [Abstract] [Full-text]
101. First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
     J Med Chem, 48(13): 4276-84. [Abstract] [Full-text]
102. CD4 binding partially locks the bridging sheet in gp120 but leaves the beta2/3 strands flexible.
     J Mol Biol, 350(3): 514-27. [Abstract] [Full-text]
103. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
     Science, 308(5730): 1906-8. [Abstract] [Full-text]
104. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
     Antimicrob Agents Chemother, 49(7): 2657-64. [Abstract] [Full-text]
105. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
     Antimicrob Agents Chemother, 49(7): 2648-56. [Abstract] [Full-text]
106. Disclosing concerns of Latinas living with HIV/AIDS.
     J Transcult Nurs, 16(3): 210-7. [Abstract] [Full-text]
107. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients.
     Lancet Infect Dis, 5(7): 407-14. [Abstract] [Full-text]
108. An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor.
     Virology, 338(1): 133-43. [Abstract] [Full-text]
109. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection.
     Virology, 338(1): 1-8. [Abstract] [Full-text]
110. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
     Virology, 338(1): 182-99. [Abstract] [Full-text]
111. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.
     Virology, 338(1): 154-72. [Abstract] [Full-text]
112. Different epidemic potentials of the HIV-1B and C subtypes.
     J Mol Evol, 60(5): 598-605. [Abstract] [Full-text]
113. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
     J Mol Biol, 350(4): 699-712. [Abstract] [Full-text]
114. The HIV fusion peptide adopts intermolecular parallel beta-sheet structure in membranes when stabilized by the adjacent N-terminal heptad repeat: a 13C FTIR study.
     J Mol Biol, 350(4): 790-805. [Abstract] [Full-text]
115. Brazil and access to HIV/AIDS drugs: a question of human rights and public health.
     Am J Public Health, 95(7): 1110-6. [Abstract] [Full-text]
116. A critical analysis of the Brazilian response to HIV/AIDS: lessons learned for controlling and mitigating the epidemic in developing countries.
     Am J Public Health, 95(7): 1162-72. [Abstract] [Full-text]
117. A review of HIV-1 Tat protein biological effects.
     Cell Biochem Funct, 23(4): 223-7. [Abstract] [Full-text]
118. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
     Protein Sci, 14(7): 1870-8. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.